Ken Griffin Biotechnology

Citadel Advisors LLC

  • $509 Billion
  • Q1 2025

Stock List

Stock Option Type Value Options Held Last Trade Trade History
IMCR
Immunocore Holdings PLC
PUT
$228,000
7.7K
Q1 2025
Reduced 29.12%
STOK
Stoke Therapeutics, Inc.
PUT
$228,000
34.3K
Q1 2025
Added 16.18%
CPRX
Catalyst Pharmaceuticals, Inc.
PUT
$227,000
9.4K
Q1 2025
Added 57.04%
CRVS
Corvus Pharmaceuticals, Inc.
CALL
$224,000
70.6K
Q1 2025
Reduced 21.64%
KURA
Kura Oncology, Inc.
CALL
$221,000
33.6K
Q1 2025
Reduced 60.05%
CDXC
Chroma Dex Corp.
CALL
$220,000
31.9K
Q1 2025
Added 301.65%
XENE
Xenon Pharmaceuticals Inc.
PUT
$218,000
6.5K
Q1 2025
Added 109.92%
VERA
Vera Therapeutics, Inc.
PUT
$216,000
9K
Q1 2025
Added 286.44%
GLPG
Galapagos Nv
PUT
$211,000
8.4K
Q4 2024
Reduced 14.84%
LIFE
A Tyr Pharma Inc
PUT
$207,000
112K
Q1 2025
Added 2011.54%
ADPT
Adaptive Biotechnologies Corp
CALL
$204,000
27.5K
Q1 2025
Reduced 36.41%
VIR
Vir Biotechnology, Inc.
PUT
$200,000
30.9K
Q1 2025
Added 496.18%
SAGE
Sage Therapeutics, Inc.
CALL
$198,000
25K
Q1 2025
Added 1144.28%
THRD
Third Harmonic Bio, Inc.
CALL
$195,000
56.3K
Q1 2025
Added 27.45%
TARA
Protara Therapeutics, Inc.
CALL
$189,000
44.4K
Q1 2025
Reduced 59.85%
VIR
Vir Biotechnology, Inc.
CALL
$187,000
28.9K
Q1 2025
Added 496.18%
VERU
Veru Inc.
PUT
$187,000
382K
Q1 2025
Reduced 43.76%
CABA
Cabaletta Bio, Inc.
PUT
$186,000
134K
Q1 2025
New holding
TPST
Tempest Therapeutics, Inc.
PUT
$181,000
18.9K
Q2 2024
Added 3074300.0%
ATAI
Atai Life Sciences N.V.
PUT
$180,000
133K
Q1 2025
Reduced 93.99%
CRDF
Cardiff Oncology, Inc.
PUT
$176,000
56.3K
Q1 2025
Added 992.73%
TRVI
Trevi Therapeutics, Inc.
PUT
$176,000
28K
Q4 2024
Added 2372.24%
ETON
Eton Pharmaceuticals, Inc.
PUT
$173,000
13.4K
Q1 2025
New holding
MREO
Mereo Biopharma Group PLC
CALL
$172,000
76.5K
Q1 2025
Added 9.46%
YMAB
Y M Abs Therapeutics, Inc.
CALL
$170,000
38.4K
Q1 2025
Reduced 30.62%
SAVA
Cassava Sciences Inc
PUT
$162,000
109K
Q1 2025
New holding
PGEN
Precigen, Inc.
CALL
$162,000
109K
Q3 2024
Reduced 8.76%
GLUE
Monte Rosa Therapeutics, Inc.
CALL
$161,000
34.9K
Q4 2024
Reduced 32.84%
FOLD
Amicus Therapeutics, Inc.
CALL
$158,000
19.4K
Q1 2025
Reduced 4.86%
ELDN
Eledon Pharmaceuticals, Inc.
PUT
$155,000
45.8K
Q1 2025
Reduced 50.49%
XERS
Xeris Biopharma Holdings, Inc.
CALL
$150,000
27.5K
Q1 2025
Added 61.74%
SANA
Sana Biotechnology, Inc.
PUT
$146,000
87.3K
Q1 2025
Added 182.25%
GALT
Galectin Therapeutics Inc
CALL
$144,000
119K
Q2 2024
Reduced 96.64%
ATAI
Atai Life Sciences N.V.
CALL
$140,000
103K
Q1 2025
Reduced 93.99%
RANI
Rani Therapeutics Holdings, Inc.
PUT
$140,000
111K
Q4 2024
Added 342.19%
ADPT
Adaptive Biotechnologies Corp
PUT
$138,000
18.6K
Q1 2025
Reduced 36.41%
ETON
Eton Pharmaceuticals, Inc.
CALL
$138,000
10.7K
Q1 2025
New holding
CGEM
Cullinan Oncology, Inc.
PUT
$135,000
17.9K
Q1 2025
Added 2.39%
GALT
Galectin Therapeutics Inc
PUT
$133,000
110K
Q2 2024
Reduced 96.64%
ABUS
Arbutus Biopharma Corp
CALL
$132,000
37.9K
Q1 2025
Reduced 45.45%
RYTM
Rhythm Pharmaceuticals, Inc.
PUT
$132,000
2.5K
Q1 2025
Added 73.35%
TYRA
Tyra Biosciences, Inc.
CALL
$132,000
14.2K
Q1 2025
Added 73.21%
CRDF
Cardiff Oncology, Inc.
CALL
$129,000
41.4K
Q1 2025
Added 992.73%
MGNX
Macrogenics Inc
PUT
$129,000
102K
Q2 2024
Reduced 94.9%
VYGR
Voyager Therapeutics, Inc.
PUT
$127,000
37.7K
Q1 2025
Added 1884.51%
CSBR
Champions Oncology, Inc.
CALL
$126,000
14.6K
Q1 2025
Added 110.73%
CVAC
Cure Vac N.V.
PUT
$125,000
45.4K
Q3 2024
Added 288.26%
AMLX
Amylyx Pharmaceuticals, Inc.
PUT
$124,000
35.3K
Q1 2025
Added 39.94%
SGMO
Sangamo Therapeutics, Inc
CALL
$121,000
185K
Q1 2025
Reduced 52.65%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email